✦ LIBER ✦

Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system

✍ Scribed by S. Thoelen; P. Van Damme; C. Mathei; G. Leroux-Roels; I. Desombere; A. Safary; P. Vandepapeliere; M. Slaoui; A. Meheus

Book ID: 117432722
Publisher: Elsevier Science
Year: 1998
Tongue: English
Weight: 794 KB
Volume: 16
Category: Article
ISSN: 0264-410X
DOI: 10.1016/s0264-410x(97)00254-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A hepatitis B vaccine formulated with a

A hepatitis B vaccine formulated with a novel adjuvant system

✍ F. Ambrosch; G. Wiedermann; M. Kundi; G. Leroux-Roels; I. Desombere; N. Garcon; 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 155 KB

A prophylactic hepatitis B vaccine with

A prophylactic hepatitis B vaccine with a novel adjuvant system

✍ Stefaan Thoelen; Norbert De Clercq; Nadia Tornieporth 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 66 KB

A controlled clinical trial comparing th

A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine

✍ Juan Dupont; Javier Altclas; Alejandro Lepetic; Mónica Lombardo; Vicente Vázquez 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 272 KB

154 Immunogenicity and safety of a novel

154 Immunogenicity and safety of a novel adjuvanted hepatitis B candidate vaccine in liver transplant patients

✍ F. Nevens; J.N. Zuckerman; A. Burroughs; M.C. Jung; J.M. Bayas; B. Kallinowski; 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 66 KB

A hepatitis B vaccine with a novel adjuv

A hepatitis B vaccine with a novel adjuvant

✍ Plotkin, Stanley A.; Schaffner, William 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 358 KB

Safety and immunogenicity of a recombina

Safety and immunogenicity of a recombinant hepatitis B vaccine

✍ E. Dandolos; A. Roumeliotou-Karayannis; S. C. Richardson; Prof. G. Papaevangelou 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 340 KB

A hepatitis B vaccine produced in yeast by recombinant DNA technology was evaluated using 5-micrograms and 10-micrograms doses in a randomized trial lasting 7 months in 110 male armed forces recruits aged 17-19 years. Results were compared to those of an identical trial of a plasma-derived vaccine.